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Abstract: Honey has been used as a wound dressing for thousands 
of years, but only in more recent times has a scientific explanation 
become available for its effectiveness. It is now realized that honey 
is a biologic wound dressing with multiple bioactivities that work in 
concert to expedite the healing process. The physical properties of 
honey also expedite the healing process: its acidity increases the re-
lease of oxygen from hemoglobin thereby making the wound environ-
ment less favorable for the activity of destructive proteases, and the 
high osmolarity of honey draws fluid out of the wound bed to create 
an outflow of lymph as occurs with negative pressure wound therapy. 
Honey has a broad-spectrum antibacterial activity, but there is much 
variation in potency between different honeys. There are 2 types of 
antibacterial activity. In most honeys the activity is due to hydrogen 
peroxide, but much of this is inactivated by the enzyme catalase that 
is present in blood, serum, and wound tissues. In manuka honey, the 
activity is due to methylglyoxal which is not inactivated. The manuka 
honey used in wound-care products can withstand dilution with sub-
stantial amounts of wound exudate and still maintain enough activity 
to inhibit the growth of bacteria. There is good evidence for honey 
also having bioactivities that stimulate the immune response (thus 
promoting the growth of tissues for wound repair), suppress inflam-
mation, and bring about rapid autolytic debridement. There is clini-
cal evidence for these actions, and research is providing scientific 
explanations for them.
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Honey: A Biologic Wound Dressing
Peter Molan, PhD1; and Tanya Rhodes, PhD2
Honey has been in use as a wound dressing for thousands of years.
1,2 
In the past few decades, there has been a large amount of clinical 
evidence has been accumulated that demonstrates the effective-
ness of honey in this application.3,4 However, it is only in more recent times 
that the science behind the efficacy has become available. It is now under-
stood that honey is not just sugar syrup with certain physical properties 
that make it suitable as a wound dressing material, but that it is a biologic 
wound dressing with multiple bioactive components that can expedite the 
healing process. 
The physical properties of honey alone will positively impact the wound 
healing environment and the healing process, specifically because honey 
is acidic and has a pH of around 3.2-4.5,5 and it is well known that topical 
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acidification of wounds promotes healing by increas-
ing the release of oxygen from hemoglobin.6 In addi-
tion, this pH is less favorable for protease activity, thus 
reducing the destruction of the matrix needed for tis-
sue repair.7 The high osmolarity of honey due to its high 
sugar content is also beneficial to the healing process, 
as substantiated in reports showing sugar pastes to be 
effective as wound dressings.8 The osmotic effect of the 
sugar draws water out of the wound bed and, although 
it could be thought that this may potentially harm and 
dehydrate the wound tissue, this is not the case. If the 
circulation of blood underneath the wound is sufficient 
to replace fluid lost from cells, then the osmotic effect 
of sugar on the surface simply creates an outflow of 
lymph.9 This outflow is beneficial to the healing process, 
as demonstrated by negative pressure wound therapy. 
Sugar also draws water out of bacterial cells and, as 
long as the sugar does not become too diluted by the 
wound fluid, the growth of bacteria is inhibited.10 The 
lowest concentration of sugar known to prevent the 
growth of Staphylococcus aureus has a water activity of 
0.86.9 Sucrose has this activity at a concentration of 67%; 
glucose at 55%; and fructose at 56%; however, it has been 
found that sucrose packed into an abdominal wound 
only maintains its activity for 4 hours before becoming 
sufficiently diluted by body fluids, allowing the water 
activity to increase to 0.897 and S. aureus to grow.11 The 
additional bioactivity within the honey itself allows for 
continued inhibition of bacterial growth even when the 
osmolarity has been diluted below the point where it 
should cease to be inhibitory. 
There has been only 1 clinical trial reported where 
honey was compared with sugar for its effectiveness,12 
in which honey was found to be more effective than 
sugar in reducing bacterial contamination and promot-
ing wound healing. In addition to this 1 comparative 
clinical trial supporting the increased antimicrobial ac-
tivity of honey, in vitro research has also been conduct-
ed13 which has provided good scientific evidence for the 
presence of bioactivity in honey. This bioactivity would 
be expected to greatly augment the effects of the physi-
cal properties on healing of wounds. 
Bioactivity of Honey
Antibacterial action. A number of reports have been 
published citing honey as having antibacterial action 
in vitro against a wide range of species of bacteria and 
fungi.13 However, in many of these studies, the minimum 
inhibitory concentration (MIC) of honey was not deter-
mined, and the concentration of honey used was high 
enough that the inhibition of microbial growth could 
have just been due to the osmotic effect of the honey. 
Also, in many of the studies, where MIC values for honey 
were reported, the type of honey used had been arbi-
trarily chosen, yet it is well known that antibacterial po-
tency can vary 100-fold between different honeys.14
 The literature reporting MIC values for honey with 
a standardized level of antibacterial activity has been 
comprehensively reviewed by Molan15 and, in these 
studies, the honeys used were selected to have antibac-
terial activity near the median level, mostly at a level 
equivalent to the standard reference antiseptic phenol 
at a concentration of 13% to 18% (weight/volume). Hon-
ey used in most products registered with the US Food 
and Drug Administration (FDA) for wound care is typi-
cally standardized to be equivalent to 12% to 16% phe-
nol. The various studies conducted with these standard-
ized honeys reported MIC values for a range of species 
of bacteria present in infected wounds: S. aureus, vari-
ous coagulase-negative Staphylococci, various species of 
Streptococci, various species of Enterococci, Pseudomo-
nas aeruginosa, Escherichia coli, Klebsiella oxytoca, 
and a range of anaerobes. 
In all cases, the MIC values were found to be below 
11%, which means even when honey is heavily diluted 
by wound exudate, it will still have more than enough 
potency of antibacterial activity to inhibit growth of bac-
teria. The various strains of methicillin-resistant Staphy-
lococcus aureus (MRSA) and vancomycin-resistant En-
terococci (VRE) tested were found to be as sensitive to 
the antibacterial activity of honey as the nonresistant 
strains of those species. Not included in the Molan15 re-
view, but covered by George and Cutting,16 was a study 
of 130 clinical isolates of multiresistant gram-negative 
bacteria to determine their sensitivity to a standardized 
honey (antibacterial potency equivalent to 18% phe-
nol).16 Minimum inhibitory concentration values of 6% 
to 8% honey were reported for Acinetobacter bauman-
nii (including 5 pan-resistant strains), for VRE and for 
Keypoints
•  Honey is a biologic wound dressing with multiple 
bioactive components that can expedite the heal-
ing process. 
•  The acidity of honey makes it less favorable for 
protease activity.
•  The high osmolarity of honey is also beneficial to 
the healing process.
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extended-spectrum beta-lactamase (ESBL)-producing 
strains of Escherichia coli, Klebsiella species, and En-
terobacter species. The MIC values for isolates of P. ae-
ruginosa were 12% to 14% honey.
There has been some concern that resistance to hon-
ey may develop in the bacteria exposed to it through 
wound care. However, in long-term “resistance training” 
experiments with 4 wound-infecting species of bacte-
ria, no permanent decrease in susceptibility to honey 
could be created and no honey-resistant mutants could 
be detected.17 It was concluded that the risk of bacte-
ria acquiring resistance to honey is low as long as high 
concentrations of honey are maintained clinically. In a 
similar study conducted by other researchers, exposure 
to sublethal concentrations of the antibiotics tetracy-
cline, oxacillin, and ciprofloxacilin rapidly induced a 
resistant phenotype in antibiotic-susceptible strains of 
S. aureus and P. aeruginosa, but constant exposure of 
these organisms to increasing sublethal concentrations 
of honey could not raise the level of resistance past the 
initial MIC of the honey.18 
Honeys not only show variation in potency of their 
antibacterial activity but also in the nature of it. In most 
of the world’s honeys, the antibacterial activity beyond 
that which is due to the osmolarity and acidity of the 
honey is due to hydrogen peroxide.13 This antibacterial 
agent is generated by glucose oxidase, an enzyme that 
bees add to the collected nectar stored in honeycombs. 
The enzyme is inactive under the low level of free wa-
ter present in honey, but becomes active if the honey 
becomes diluted, as with wound exudate.19 Although 
honey diluted to 25% with water can still exhibit anti-
bacterial activity equivalent to that of an 8% solution of 
phenol in laboratory testing, it will be much less active 
in a wound scenario because serum and wound tissue 
contain the enzyme catalase which rapidly breaks down 
hydrogen peroxide. Any visible antibacterial activity 
seen with the 25% solution of honey tested in the labo-
ratory would be removed if blood at a concentration of 
1% is added to the agar plates.
Honey from manuka trees (and some other members 
of the Leptospermum genus) has a unique type of anti-
bacterial activity not due to hydrogen peroxide, and as 
such, is not affected by the catalase enzyme activity in 
wounds. Its antibacterial activity is due to methylgloxal, 
which forms by spontaneous conversion in ripened 
honey from its precursor substance dihydroxyacetone 
that is found in manuka nectar.20 Methylglyoxal on its 
own is a cytotoxic substance, and the possibility has 
been raised that the methylglyoxal in manuka honey 
may contribute to delayed wound healing in patients 
with diabetes.21 It would seem however, that the com-
bination and ratio with other components in the ma-
nuka honey counteracts the methylglyoxal component 
from exhibiting such toxicity, because no cytotoxicity 
is seen in the required testing for FDA registration of 
manuka honey wound-care products. In addition, clini-
cal results obtained using manuka honey on patients 
with diabetes indicate that rapid healing is achieved—
diabetic leg ulcers that had been nonhealing for long 
periods healed mostly within 3 months when dressed 
with manuka honey.22
The antibacterial component of manuka honey is a 
small water-soluble molecule that diffuses easily, which 
explains why manuka honey has also exhibited efficacy 
against bacteria contained in biofilms. Prolonged chro-
nicity of wounds can be attributed to wound coloniza-
tion that develops into a biofilm in which the bacteria 
stay protected by the matrix of the biofilm. These bac-
teria cannot be cleared by the host immune system and 
show resistance to both systemic and topical antimicro-
bial agents.23 This may explain why antibiotics are of 
limited use in treating chronic wounds.23 Manuka honey 
at a concentration of 40% has been found to give signifi-
cantly reduced biofilm biomass with in vitro testing of 
clinical isolates of P. aeruginosa that had developed into 
a biofilm.24 A similar finding was made in a comparable 
study conducted with Streptococcus pyogenes.25 In an-
other study conducted with biofilms developed from 11 
isolates each of methicillin-sensitive S. aureus (MSSA), 
Keypoints
•  Honey used in most products registered with the 
US Food and Drug Administration for wound care 
is typically standardized to be equivalent to 12% 
to 16% phenol.
•  The various studies conducted with these stan-
dardized honeys reported minimum inhibitory con-
centration (MIC) values for a range of species of 
bacteria present in infected wounds: S. aureus, 
various coagulase-negative Staphylococci, various 
species of Streptococci, various species of Entero-
cocci, Pseudomonas aeruginosa, Escherichia coli, 
Klebsiella oxytoca, and a range of anaerobes.
•  In all case, MIC values were found to be below 
11%; even when honey is heavily diluted by wound 
exudate, it will still have potent enough antibacte-
rial activity to inhibit growth of bacteria.
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MRSA, and P. aeruginosa, it was found that 50% manuka 
honey killed 9 out of 11, 7 out of 11, and 10 out of 11 of 
the isolates, respectively.26 Greater sensitivity was found 
in another study on biofilms formed in vitro where the 
MIC for manuka honey was 6% honey for MRSA and 
methicillin-resistant S. epidermidis, and 12% honey for P. 
aeruginosa and ESBL Klebsiella pneumoniae.27 
Clinically, there have been many reports28-31 published 
of manuka honey being effective in achieving healing 
of chronic wounds. One of these was an observational 
study where 20 patients with spinal cord injuries who 
had chronic pressure ulcers (5 had grade IV ulcers and 
15 had grade III ulcers) were treated with manuka hon-
ey.28 After 1 week of treatment with manuka honey all 
swabs were void of bacterial growth, and after a period 
of 4 weeks, 18 patients showed complete wound heal-
ing. Another study29 examined 40 patients with leg ul-
cers that had not responded to 12 weeks of compression 
therapy. Manuka honey dressings were applied to the ul-
cers for a 12-week study period. Overall, ulcer pain and 
size decreased significantly and odorous wounds were 
deodorized promptly. Average pain score as measured 
on the McGill Pain Index scale had decreased from 1.6 ± 
1.22 to 1.08 ± 1.54 by the individual patients’ endpoints. 
The average rate of reduction in wound area was 5.46%. 
At first assessment (after 2 weeks) the average score for 
odor had decreased from 1.58 ± 0.90 to 0.69 ± 0.79 (on 
a scale where 3 indicated severe odor), with 11/26 (42%) 
having no odor.29 A further study30 showed a group of 
8 patients with nonhealing or recurrent venous leg ul-
cers treated with manuka honey healed with acceler-
ated wound closure, and a study31 of 11 cases involving 
only nonhealing venous ulcers that did not respond to a 
variety of usual treatment options showed that wounds 
treated with manuka honey dressings had complete clo-
sure in 3 to 6 weeks. There have also been many reports 
of single case studies where manuka honey resulted in 
healing of previously nonhealing wounds.32-39
Immunostimulatory action. It is possible that the 
clearance of infection by the antibacterial activity of 
honey may be further augmented by its immunostim-
ulatory action, although there will always be some at-
tenuation of this by the anti-inflammatory activity of 
honey. Whether or not the stimulation of the immune 
response contributes to wound healing by helping sup-
press infection, it will definitely contribute to healing 
through the stimulation and growth of repair tissue. It 
is a commonly reported clinical observation that rap-
id healing is achieved when wounds are dressed with 
honey,3,4 and similar observations have been made in 
numerous animal experiments.40 These results could 
be considered a consequence of the honey suppress-
ing infection; however, in experiments where dermal 
burn wounds were inflicted on pigs41,42 and rats43 under 
surgical conditions, the wounds created were free from 
bacteria and the rate of healing was still increased upon 
the application of honey.
Work in vitro has demonstrated that the immunos-
timulatory activity of honey on leukocytes causes the 
production of cytokines, which leads to the stimulation 
and growth of cells. Honey at a concentration of 1% was 
found to stimulate release of tumor necrosis factor alpha 
(TNF-α) by monocytes.44 Although stimulation of inflam-
mation is generally considered to be harmful, there is a 
modulation of this inflammatory response by the anti-in-
flammatory activity of honey. Thus, when 1% honey was 
added to inflamed macrophages formed by activation of 
monocytes by lipopolysaccharide and opsonized zymo-
san, there was no increase in the the release of TNF-α, 
and the honey suppressed the production of reactive 
oxygen intermediates formed in the respiratory burst.44
In a similar study, honey at a concentration of 1% was 
found to stimulate the release of TNF-α, interleukin-1 
beta (IL-1β), and IL-6 from monocytes, cytokines known 
in vivo to play a role in tissue repair.45 Keratinocytes have 
been found to have transcription of the genes for the cy-
tokines TNF-α, IL-1β, and TGF-α upregulated by honey at 
a concentration of 1%.46 In addition, honey upregulated 
the gene for matrix metallopeptidase 9 (MMP-9), which 
is a protease that detaches keratinocytes from the base-
ment membrane to allow their migration in reepitheli-
alization.46 Reepithelialization would also be promoted 
by increased levels of TNF-α and IL-1β, which induce the 
production of the keratinocyte growth factor fibroblast 
growth factor 7.46 Honey has also been demonstrated to 
stimulate angiogenesis in vitro47 in a rat aortic ring assay, 
maximally at around a concentration of honey of 0.2%.
Keypoints
•  Honey from manuka trees (and some other mem-
bers of the Leptospermum genus) has a unique 
type of antibacterial activity that is not due to hy-
drogen peroxide, and as such is not affected by the 
catalase enzyme activity in wounds.
•  Manuka honey at a concentration of 40% has been 
found to give significantly reduced biofilm biomass 
with in vitro testing of clinical isolates of P. aerugi-
nosa that had developed into a biofilm.24
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This immunostimulatory activity of honey has been 
attributed to various components by different authors: 
major royal jelly protein-1 (MRJP-1), arabinogalactan, en-
dotoxin contaminant in honey, and a substance of mo-
lecular weight 5.8 kDa.48 Major royal jelly protein-1 was 
found to make only a minor contribution to the stimu-
lation of keratinocytes, hence it was concluded that 
another component must be responsible.46 In a study 
of stimulation of release of TNF-α by monocytes, it was 
found that the arabinogalactan-protein complex isolated 
from honey needed to be at a concentration of more 
than 25 μg/ml to give the amount of stimulation given 
by 0.5% honey but, upon calculation, the stated concen-
tration of arabinogalactan-protein complex in the honey 
(10 μg/g)  meant that 0.5% honey contained only 0.05 
μg/ml of arabinogalactan.49 The possibility that stimula-
tion was due to endotoxin was ruled out, and so the 
major immunostimulatory factor was concluded to be 
an unidentified component of molecular weight 5.8 kDa 
that is not a protein.50 This unidentified component has 
been found to work through stimulation of the toll-like 
receptor 4 on leukocytes.50
Anti-inflammatory action. Honey has a long his-
tory of use as an anti-inflammatory substance. The an-
cient Greek physician and pharmacologist Pedanius Di-
oscorides used honey to treat sunburn and spots on the 
face, as well as to heal inflammation of the throat and 
tonsils.51 In the modern era, there have been numerous 
observations of honey applied to inflamed wounds and 
burns resulting in reduced edema and exudate, provid-
ing a soothing effect, and minimizing scarring.52 In clini-
cal trials on burns comparing honey with silver sulfadia-
zine, honey showed decreased levels of the marker for 
inflammation, decreased levels of malondialdehyde,53 
and a reduced number of inflammatory cells present in 
biopsy samples.54 The numerous reports of anti-inflam-
matory activity in experimental wounds and burns of 
animal models, where there were few or no bacteria 
present (due to aseptically produced wounds),52 indi-
cate honey has a direct anti-inflammatory activity, the 
decrease in inflammation not simply being a secondary 
effect of the antibacterial activity of honey removing 
inflammation-causing bacteria.
The anti-inflammatory activity of honey has also been 
demonstrated in clinical trials to reduce the severity 
of mucositis in radiotherapy of the head and neck re-
gion,55-58 and to treat gingivitis.59 Anti-inflammatory ac-
tivity has also been seen in clinical trials to treat dys-
pepsia60 and found to be effective in the relief of various 
ophthalmological inflammatory conditions.61 Honey has 
been found to decrease pain after surgical removal of 
children’s tonsils,62 and also to decrease pain in nonheal-
ing leg ulcers.29 In experiments with rats, honey dem-
onstrated a highly significant reduction in peritoneal 
adhesions following surgery on the cecum,63 efficacy as 
a treatment for chemically induced colitis,64-67 and pre-
vention of gastritis caused by administered dosage of 
ethanol.68-70 Injection of 50% honey into rat paws prior 
to injecting lipopolysaccharide to cause inflammation 
resulted in less swelling, reduced sensitivity to pain, and 
a lower level of inflammatory markers.71 In a study of 
carrageenan-induced edema in rat paws, pretreatment 
with oral doses of honey gave a dose-dependent reduc-
tion in the edema and a suppression in expression of the 
genes for inducible nitric oxide synthase, COX-2, TNF-α, 
and IL-6.72 
This well-documented anti-inflammatory activity in 
honey has been attributed to the present plant pheno-
lic compounds73; however, no correlation was found be-
tween the level of anti-inflammatory activity observed 
in various honeys and the known phenolic compounds 
present.74 A wide range of varieties of honeys were 
tested for anti-inflammatory activity: pasture honey, clo-
ver honey, kanuka honey buttercup honey, and beech 
honeydew honey.75 Phenolic components may well be 
involved, as they are as a class of compound known to 
inhibit the production of the inflammatory cytokine 
TNF-α,76 but more recently, another major anti-inflam-
matory component of honey has been identified that 
is not a phenolic compound but rather a protein that 
works in a different way.77 This bee-derived protein, ap-
albumin-1, was identified as the component of honey 
that inhibits phagocytosis by macrophages, the first 
Keypoints
•  Clinical observation shows rapid healing is 
achieved when wounds are dressed with honey,3,4 
and similar observations have been made in nu-
merous animal experiments.40
•  Work in vitro has demonstrated that the immuno-
stimulatory activity of honey on leukocytes causes 
the production of cytokines, which lead to the 
stimulation and growth of cells.
•  This immunostimulatory activity of honey has been 
attributed to various components: major royal jelly 
protein-1 (MRJP-1), arabinogalactan, endotoxin 
contaminant in honey, and a substance of molecu-
lar weight 5.8 kDa.48
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step in the sequence of an inflammatory response to 
necrotic tissue and/or microbial cells. It was found that 
manuka honey is a much stronger inhibitor of phagocy-
tosis than other types of honey. It was determined that 
methylglyoxal, a substance found in significant quan-
tities only in manuka honey, reacts with apalbumin-1 
to glycate it, and this glycated apalbumin-1 is a much 
stronger inhibitor of phagocytosis than the unmodified 
apalbumin-1 generally found in other types of honey. A 
0.5% solution of manuka honey gave 67% inhibition of 
phagocytosis. The mechanism of action of apalbumin-1, 
both the glycated and unmodified forms, is by blocking 
the mannose receptor on phagocytes which is the trig-
ger for phagocytosis.77
Debriding action. Debridement of wounds using 
honey dressings has been observed in clinical trials on 
burns.54,78,79 In one such trial,54 honey was found to pre-
vent the formation of eschar, whereas eschar formed 
in the cases treated with silver sulfadiazine. Seven case 
series and ten single case studies in which honey was 
reported to be effective in debriding wounds have been 
outlined in a review of the clinical evidence for the ef-
fectiveness of honey as a debriding agent.80
Clinical trials have also shown honey is a good al-
ternative to surgical debridement for the treatment of 
necrotizing fasciitis in the genital region.81-83 In a clinical 
trial comparing honey with hydrogel for debridement 
of wounds, it was found that better debridement was 
obtained with honey, although there was not a statisti-
cally significant difference.84 The results were compared 
with those published from other studies, and it was 
concluded that in the desloughing of venous leg ulcers, 
manuka honey is slower than larval therapy or curet-
tage but superior to some hydrogels, enzymatic agents, 
hydrocolloids, paraffin gauze, or cadexomer iodine. In a 
trial on adjacent experimental rabbit wounds, wounds 
treated with honey-soaked gauze were kept clean while 
wounds treated with saline-soaked gauze formed thick 
dense scabs.85 
A possible explanation for the mechanism by which 
honey brings about debridement of wounds has recent-
ly been discovered.86 It was hypothesized that honey 
increases the activity of plasmin, an enzyme that specifi-
cally digests fibrin (fibrin attaches slough to the wound 
surface) but does not digest the collagen matrix need-
ed for tissue repair. In work with cultures of inflamed 
macrophages it was demonstrated that honey increased 
plasmin activity in the culture medium, and that the 
plasmin activity increased because the honey inhibited 
the production of plasminogen activator inhibitor (PAI) 
by the macrophages. Plasminogen activator inhibitor 
normally blocks the conversion of plasminogen (the en-
zymically inactive precursor of plasmin) into active plas-
min. Inflammation increases production of PAI,87 so it is 
to be expected that honey would lead to a decrease in 
production of PAI because of the well-established anti-
inflammatory activity of honey.
Conclusion
Honey is a biologic wound dressing with multiple 
bioactivities. Each of the healing-promoting activities 
can be found separately in pharmaceutical products, 
but in honey they are all present and work together syn-
ergistically to enhance the healing process. In addition, 
there is the added benefit from the physical properties 
of the honey creating a moist healing environment, one 
in which the antibacterial activity removes all likelihood 
of moist conditions favoring bacterial growth. Bacterial 
infection and critical colonization can inhibit healing, 
either through the direct effects of bacteria on wound 
tissue, or through the deleterious effects of excessive 
inflammation,88 but the combination of antibacterial 
Keypoints
•  In clinical trials on burns comparing honey with 
silver sulfadiazine, honey showed decreased levels 
of the marker for inflammation, decreased levels 
of malondialdehyde,53 and a reduced number of 
inflammatory cells present in biopsy samples.54
•  Honey has been found to decrease pain after sur-
gical removal of children’s tonsils,62 and also to 
decrease pain in nonhealing leg ulcers.29
•  Injection of 50% honey into rat paws prior to in-
jecting lipopolysaccharide to cause inflammation 
resulted in less swelling, reduced sensitivity to 
pain, and a lower level of inflammatory markers.71
Keypoints
•  Seven case series and ten single case studies in 
which honey was reported to be effective in debrid-
ing wounds have been outlined in a review of the 
clinical evidence for the effectiveness of honey as 
a debriding agent.80
•  It has been hypothesized that honey increases the 
activity of plasmin, an enzyme that specifically di-
gests fibrin (fibrin attaches slough to the wound 
surface) but does not digest the collagen matrix 
needed for tissue repair.
Rhodes_0615.indd   146 6/8/15   12:34 PM
Molan and Rhodes
Vol. 27,  No. 6  June 2015  147 
and anti-inflammatory activity within honey, along with 
the debriding action of detaching slough (which is a 
harbor for inflammation-causing bacteria), may explain 
why honey can so readily bring about the healing of 
chronic wounds. It should be noted that there are situa-
tions where a stagnated healing process can be re-start-
ed by inflammation, and research has been conducted 
that shows wound healing can be improved to a certain 
extent by inoculation of live staphylococci, but only by 
very low bacterial concentrations that promote a local 
inflammatory response but are not sufficient to slow 
healing.89 It is believed that the immunostimulatory ac-
tion of honey, modulated by the anti-inflammatory ac-
tivity, gives a similar effect. This would account for the 
observations that honey kick-starts healing of chronic 
wounds that have remained nonhealing for long peri-
ods of time.90-93 
It is necessary to keep the honey present at the 
wound bed interface for these bioactivities to work. 
This is achieved by the use of primary dressings in 
which the honey is impregnated in an absorbent mate-
rial. An optimal primary dressing would be one that can 
absorb wound exudate and provide constant exposure 
and contact of the wound with honey. Three different 
types of such dressings are available: an alginate dress-
ing (Algivon Dressings, Advancis Medical, Kirby in Ash-
field, Nottingham, UK, and Medihoney Apinate Alginate 
Dressing, Derma Sciences, Princeton, NJ); a polyacrylate 
gel dressing (Manuka Health Wound Dressings, Manuka 
Health New Zealand Ltd, Auckland, NZ); and a dressing 
based on superabsorbent fibers (ManukaHD,  Manuka-
Med, Largo, FL).
One has honey impregnated into an alginate fiber 
dressing which converts to a gel when exposed to 
wound fluid, but has a relatively limited capacity to 
absorb fluid. Another has the honey incorporated in a 
polyacrylate gel that has the capacity to absorb wound 
fluid and swell. The third type has honey impregnated 
into the interstitial spaces of a dressing composed of 
superabsorbent fibers.  These fibers have a high capac-
ity to absorb wound fluid and expand without losing 
structure while simultaneously absorbing the mixture 
of honey and wound fluid from the interstitial spaces 
and allowing continued diffusion of honey into the 
wound bed.
Honey can be used on any type of wound at any 
stage of healing, but certain precautions should be 
noted. The honey should always be sterilized since, 
although vegetative bacterial cells in honey are killed 
by the honey itself, bacterial spores are not. Spores of 
Clostridium may sometimes occur in honey and could 
theoretically germinate in necrotic tissue if left there 
once honey has been diluted to a subinhibitory con-
centration by wound exudate. Sterilization should be 
done by gamma-irradiation, not heat, which would de-
stroy the antibacterial activity. In addition, much of the 
manuka honey available for purchase, other than that 
which is registered as a wound-care product, has little 
or no methylglyoxal in it. There are even some wound-
care products made with non-manuka honey that do 
not contain any methylglyoxal. The antibacterial activ-
ity of non-manuka honey products would be due to the 
sugar content and hydrogen peroxide. The inhibitory 
action of the sugar would be lost as the honey is diluted 
by wound exudate, and the hydrogen peroxide would 
be destroyed by the activity of catalase which is pres-
ent in serum and wound tissues. On inflamed wounds, 
honey may cause mild transient pain. This is because 
inflammation sensitizes the nocioceptor nerve endings 
which may then respond to the acidity of honey. The 
use of honey dressings in which the honey is gelled or 
provides for slow release reduces the impact of acidity 
Keypoints
•  The inadequacy of comparative randomized trials 
for wound dressings in general, and the difficulties 
faced in obtaining high quality evidence, has been 
discussed.
•  Leaper98 noted when clinical evidence of the high-
est level is not available, decisions on modes of 
treatment need to be based on whatever evidence 
is available. 
•  Although the criticism of the quality of the avail-
able studies is well taken, there have been at least 
35 randomized controlled trials published on the 
use of honey in a wide range of wound types, with 
a total of 3,655 participants.3,4,99,100
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•  Honey should always be sterilized by gamma-irra-
diation, not heat, which would destroy the antibac-
terial activity.
•  From a clinical perspective, there is a vast amount 
of evidence to support the use of honey in wound 
care;3,4 however, some reviews have still concluded 
there is a lack of true clinical evidence due to the 
absence of high quality controlled or comparative 
randomized studies.94,95 
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in the wound, resulting in less pain than if plain honey 
or honey-impregnated gauze dressings are applied.
From a clinical perspective, there is a vast amount of 
evidence to support the use of honey in wound care;3,4 
however, some reviews have still concluded there is a 
lack of true clinical evidence due to the absence of high 
quality controlled or comparative randomized stud-
ies.94,95 Campbell96 has referred to the hierarchy of evi-
dence ranging from double-blind randomized controlled 
trials giving the strongest evidence, through other forms 
of randomized controlled trials, non-randomized studies, 
controlled case studies, then case studies. It is important 
to note the US FDA does not require such high level 
evidence-based trials to be conducted and, therefore, 
there is a similar lack of high-quality studies for any of 
the dressings currently used in standard modern wound 
care.4,97 The inadequacy of comparative randomized tri-
als for wound dressings in general, and the difficulties 
faced in obtaining high quality evidence, has been dis-
cussed by Leaper98 who made the point that when clini-
cal evidence of the highest level is not available, then 
decisions on modes of treatment need to be based on 
whatever evidence is available. Although the criticism 
of the quality of the available studies is well taken, there 
have been at least 35 randomized controlled trials pub-
lished on the use of honey in a wide range of wound 
types, with a total of 3,655 participants.3,4,99,100 This is in 
addition to the large number of case studies and small 
trials that are published and continue to be published. 
Therefore, the authors conclude that the available evi-
dence supports honey, and manuka honey specifically, 
as an important tool for wound care.
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